The data showed that there were no individuals identified with two CYP21A2 variants or other genes in 647 newborns except for six patients with CAH, which indicates that the cut-off value applied in 17α-OHP screening leads to more false positive results and unnecessary recalling. The gene discussed is CYP21A2; the disease is congenital adrenal hyperplasia.